| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ISLAND PHARMACEUTICALS LIMITED: Cleansing Notice | - | ASX | ||
| Mo | ISLAND PHARMACEUTICALS LIMITED: Application for quotation of securities - ILA | - | ASX | ||
| ISLAND PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | ISLAND PHARMACEUTICALS LIMITED: Quarterly Appendix 4C and Activities Report | - | ASX | ||
| 30.03. | ISLAND PHARMACEUTICALS LIMITED: Cleansing Notice | - | ASX | ||
| 30.03. | ISLAND PHARMACEUTICALS LIMITED: Application for quotation of securities - ILA | - | ASX | ||
| 23.03. | ISLAND PHARMACEUTICALS LIMITED: Cleansing Notice | 1 | ASX | ||
| 23.03. | ISLAND PHARMACEUTICALS LIMITED: Application for quotation of securities - ILA | 3 | ASX | ||
| 09.03. | Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding | 1 | smallcaps.com.au | ||
| 08.03. | ISLAND PHARMACEUTICALS LIMITED: Antiviral pipeline expansion through strategic collaboration | - | ASX | ||
| 04.03. | XFRA 7X0: WIEDERAUFNAHME/RESUMPTION | 202 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 04.03. | Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold | 3 | Finance News Network | ||
| 04.03. | Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule | 1 | smallcaps.com.au | ||
| 03.03. | ISLAND PHARMACEUTICALS LIMITED: US Government collaboration for Galidesivir development | - | ASX | ||
| 02.03. | XFRA 7X0: AUSSETZUNG/SUSPENSION | 140 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILISLAND PHARMACEUT.LTD... ► Artikel lesen | |
| 01.03. | ISLAND PHARMACEUTICALS LIMITED: Trading Halt | - | ASX | ||
| 25.02. | ISLAND PHARMACEUTICALS LIMITED: Appendix 4D & Half-Year Financial Statements | - | ASX | ||
| 15.02. | ISLAND PHARMACEUTICALS LIMITED: Cleansing Notice | - | ASX | ||
| 15.02. | ISLAND PHARMACEUTICALS LIMITED: Application for quotation of securities - ILA | - | ASX | ||
| 10.02. | ISLAND PHARMACEUTICALS LIMITED: Response to ASX Query Letter | - | ASX | ||
| 04.02. | ISLAND PHARMACEUTICALS LIMITED: Investor presentation | 1 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,350 | +3,07 % | Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update | Company Highlights Commercial Launch of DARE to PLAY Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,110 | +3,80 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,905 | +0,79 % | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,400 | +4,93 % | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen |